Business Wire

25 Years of Making the World a Better Place for Women: Mary Kay Ash FoundationSM Marks Milestone Anniversary

10.11.2021 16:43:00 EET | Business Wire | Press release

Share

In celebration of its 25th anniversary and guided by Mary Kay Ash’s dream to enrich the lives of women worldwide, the Mary Kay Ash FoundationSM released its first-ever Foundation Annual Report, as well as a new name, logo website and rebranding. Since 1996, the Foundation has contributed more than $80 million to organizations aligned with its two-fold mission: funding research for cancers affecting women and ending domestic violence and gender-based violence against women and girls.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005237/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Mary Kay Ash Foundation℠ logo (Graphic: Mary Kay Inc.)

For more than two decades, the Foundation has continued to innovate as a global charitable leader focused on women. To commemorate its milestone anniversary, the organization made a slight name change from The Mary Kay FoundationSM to Mary Kay Ash FoundationSM to improve search engine optimization. In addition, the Foundation unveiled a new logo and website, rebranding and the first-ever Mary Kay Ash FoundationSM Annual Report. The report gives an overview of the 2020 initiatives in the United States and around the world. Key findings in the report include:

  • In 2020, the Mary Kay Ash FoundationSM awarded grants totaling $1,825,000 to causes in the U.S. and those that will make a difference throughout the world via the Innovative/Translational Cancer Research Grants and the International Post-Doctoral Fellowship Cancer Research Program. Since 1996, the Mary Kay Ash FoundationSM has supported innovative cancer research and clinical trials to find a cure for cancers affecting women by awarding more than $25 million for over 250 cutting-edge projects at leading medical schools and research institutions worldwide.
  • Due to the COVID-19 pandemic, a devastating increase was reported in domestic violence across the world in 2020. This pandemic within a pandemic stretched domestic violence shelters to their limits. The Mary Kay Ash FoundationSM awarded emergency grants totaling $1,000,000 to support domestic violence frontline workers – the first responders for women and children. In an effort to expand a global commitment to eradicate gender-based domestic violence, Mary Kay Inc. and the Mary Kay Ash FoundationSM joined forces with the United Nations Trust Fund to End Violence Against Women and CARE USA, humanitarian global leaders. Since 2000, the Foundation has donated more than $58 million to ending gender-based violence. The effort has supported over six million women and girls seeking shelter and services from abuse.

“Twenty-five years ago, my grandmother, Mary Kay Ash, created the Foundation that continues to remain at the heart of Mary Kay Inc., company employees and independent beauty consultants who strive to uphold her vision of making the world a better place for women and their families,” said Ryan Rogers, Chief Investment Officer and Vice President of the Mary Kay Ash FoundationSM Board of Directors. “While the Mary Kay Ash FoundationSM planted its roots in Texas and watched them spread across the United States, much like the company itself, the work of the Foundation knows no borders. We envision a world where women are empowered, healthy and safe. On this milestone anniversary, we continue our steadfast commitment to women worldwide and are reminded of how truly honored we are to continue doing my grandmother’s work.”

For more information, visit marykayashfoundation.org.

About the Mary Kay Ash FoundationSM

Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers and ending domestic violence against women. Since 1996, the Mary Kay Ash FoundationSM has contributed more than $80 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayashfoundation.org, find us on Facebook and Instagram, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye